Muhammad Ajmal1, Mathew D Hutchinson1, Kwan Lee1, Julia H Indik2. 1. Sarver Heart Center, University of Arizona College of Medicine, 1501 N Campbell Ave, Tucson, AZ, 85724-5037, USA. 2. Sarver Heart Center, University of Arizona College of Medicine, 1501 N Campbell Ave, Tucson, AZ, 85724-5037, USA. jindik@email.arizona.edu.
Abstract
BACKGROUND: Patients with atrial fibrillation are increasingly prescribed a direct oral anticoagulant (DOAC) over warfarin and seek to avoid anticoagulation even without a history of major bleeding. This study explores the outcomes of patients implanted with a Watchman device in relation to anticoagulation choice (warfarin versus DOAC) in the post-procedure period and a history of bleeding. METHODS: Patients implanted with a Watchman device at a single center were retrospectively analyzed. Characteristics including anticoagulation in the first 45 days and history of major bleed were assessed and efficacy (thromboembolism) and safety (bleeding) outcomes compared by Kaplan-Meier analysis. RESULTS: Two hundred nine patients were implanted (57% male, age 74.6 ± 7.8 years) and followed for 23.5 ± 7.1 months. In the first half of patients, 98% were prescribed warfarin, which dropped to 51% in the second half (p < 0.0001). A history of major bleed was present in 80.8% of the first half of patients and decreased to 60% in the second half (p = 0.001). There were 16 safety and 4 efficacy events. There was no difference in safety outcomes according to history of major bleeding or anticoagulant choice in the first 45 days. There was no difference in efficacy outcomes over the duration of follow-up according to anticoagulation choice in the first 45 days. CONCLUSIONS: Patients implanted with a Watchman device were increasingly over time prescribed a DOAC and implanted without a history of major bleeding. Bleeding and thromboembolic events were infrequent and related neither to choice of anticoagulant nor to prior major bleeding.
BACKGROUND: Patients with atrial fibrillation are increasingly prescribed a direct oral anticoagulant (DOAC) over warfarin and seek to avoid anticoagulation even without a history of major bleeding. This study explores the outcomes of patients implanted with a Watchman device in relation to anticoagulation choice (warfarin versus DOAC) in the post-procedure period and a history of bleeding. METHODS: Patients implanted with a Watchman device at a single center were retrospectively analyzed. Characteristics including anticoagulation in the first 45 days and history of major bleed were assessed and efficacy (thromboembolism) and safety (bleeding) outcomes compared by Kaplan-Meier analysis. RESULTS: Two hundred nine patients were implanted (57% male, age 74.6 ± 7.8 years) and followed for 23.5 ± 7.1 months. In the first half of patients, 98% were prescribed warfarin, which dropped to 51% in the second half (p < 0.0001). A history of major bleed was present in 80.8% of the first half of patients and decreased to 60% in the second half (p = 0.001). There were 16 safety and 4 efficacy events. There was no difference in safety outcomes according to history of major bleeding or anticoagulant choice in the first 45 days. There was no difference in efficacy outcomes over the duration of follow-up according to anticoagulation choice in the first 45 days. CONCLUSIONS: Patients implanted with a Watchman device were increasingly over time prescribed a DOAC and implanted without a history of major bleeding. Bleeding and thromboembolic events were infrequent and related neither to choice of anticoagulant nor to prior major bleeding.
Authors: Pavel Osmancik; Dalibor Herman; Petr Neuzil; Pavel Hala; Milos Taborsky; Petr Kala; Martin Poloczek; Josef Stasek; Ludek Haman; Marian Branny; Jan Chovancik; Pavel Cervinka; Jiri Holy; Tomas Kovarnik; David Zemanek; Stepan Havranek; Vlastimil Vancura; Jan Opatrny; Petr Peichl; Petr Tousek; Veronika Lekesova; Jiri Jarkovsky; Martina Novackova; Klara Benesova; Petr Widimsky; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2020-06-30 Impact factor: 24.094
Authors: Vivek Y Reddy; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Jonathan L Halperin; David Holmes Journal: Circulation Date: 2013-01-16 Impact factor: 29.690
Authors: Vivek Y Reddy; Sven Möbius-Winkler; Marc A Miller; Petr Neuzil; Gerhard Schuler; Jens Wiebe; Peter Sick; Horst Sievert Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094
Authors: David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy Journal: J Am Coll Cardiol Date: 2014-07-08 Impact factor: 24.094
Authors: James V Freeman; Paul Varosy; Matthew J Price; David Slotwiner; Fred M Kusumoto; Chidambaram Rammohan; Clifford J Kavinsky; Zoltan G Turi; Joseph Akar; Cristina Koutras; Jeptha P Curtis; Frederick A Masoudi Journal: J Am Coll Cardiol Date: 2020-04-07 Impact factor: 24.094
Authors: Adam J Rose; Robert Goldberg; David D McManus; Alok Kapoor; Victoria Wang; Weisong Liu; Hong Yu Journal: J Am Heart Assoc Date: 2019-08-23 Impact factor: 5.501